{"id":"yzj-1139","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"5-10%","effect":"Increased urination"}]},"_chembl":{"chemblId":"CHEMBL5847558","moleculeType":null,"molecularWeight":"512.56"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"YZJ-1139 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes. By reducing glucose reabsorption, YZJ-1139 also has a secondary effect of reducing blood pressure and fluid overload.","oneSentence":"YZJ-1139 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:14.776Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT06975514","phase":"PHASE3","title":"Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder","status":"RECRUITING","sponsor":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","startDate":"2025-03-25","conditions":"Insomnia Disorder","enrollment":60},{"nctId":"NCT06673927","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants","status":"COMPLETED","sponsor":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","startDate":"2017-12-01","conditions":"Insomnia","enrollment":104},{"nctId":"NCT06685341","phase":"PHASE1","title":"PK/PD Study of YZJ-1139","status":"COMPLETED","sponsor":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","startDate":"2019-03-07","conditions":"Insomnia","enrollment":20},{"nctId":"NCT06680505","phase":"PHASE2","title":"Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder","status":"COMPLETED","sponsor":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","startDate":"2019-08-04","conditions":"Insomnia Disorder","enrollment":300},{"nctId":"NCT06680531","phase":"PHASE1","title":"A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","startDate":"2024-08-31","conditions":"Insomnia, Central Nervous System","enrollment":24},{"nctId":"NCT06671444","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","startDate":"2024-06-03","conditions":"Insomnia, Renal Impairment","enrollment":16},{"nctId":"NCT06671509","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment","status":"COMPLETED","sponsor":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","startDate":"2024-03-22","conditions":"Insomnia, Hepatic Impairment","enrollment":24},{"nctId":"NCT06671470","phase":"PHASE1","title":"A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","startDate":"2024-08-22","conditions":"Insomnia","enrollment":27},{"nctId":"NCT05525637","phase":"PHASE3","title":"Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder","status":"RECRUITING","sponsor":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","startDate":"2021-12-17","conditions":"Insomnia Disorder","enrollment":1041}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"YZJ-1139","genericName":"YZJ-1139","companyName":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","companyId":"shanghai-haiyan-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"YZJ-1139 is an orally administered medication being developed for the treatment of insomnia. It is an orexin receptor antagonist, as indicated by its classification as Fazamorexant.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}